Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up.

All groups of autoimmune hemolytic anemia are associated with increased overall and cause-specific mortality compared to the general population. This probably reflects unmet needs in both treatment and follow-up programs.